Skip to main content

NCCN Guidelines® Insights: Colon Cancer, Version 3.2026

In brief

Colon cancer guidelines add pretreatment toxicity screening and refine biomarker-based therapy

The 2026 update recommends testing for dihydropyrimidine dehydrogenase gene variants before fluoropyrimidine treatment to help prevent severe toxicity, revises adjuvant therapy recommendations for nonmetastatic disease, and organizes systemic options for advanced or metastatic cancer by biomarker status. It also changes recommendations for BRAF V600E-positive disease; the abstract does not specify preferred regimens or quantify clinical benefit.

Journal
Journal of the National Comprehensive Cancer Network : JNCCN (Q1)
Published
1 November 2026
Study design
Practice guideline / consensus
Evidence level
Level 1, High (CEBM 1c)
Authors
Al B Benson, Alan P Venook, Mohamed Adam, Manju Ambelil, Alexander Bray, George J Chang, et al.
PMID
43019762
DOI
10.6004/jnccn.2026.0051

Why clinicians should know about it

Abstract

Colorectal cancer is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. Treatment of localized disease usually includes surgery, sometimes followed by adjuvant systemic therapy, while advanced or metastatic disease is often treated with multiple lines of systemic therapy, based on biomarker status. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Colon Cancer, including recommendations for pretreatment DPYD testing to decrease the risk of severe fluoropyrimidine toxicity; updates to adjuvant therapy of nonmetastatic colon cancer based on the results of recent clinical trials; and a reorganization of the systemic therapies for advanced or metastatic disease based on biomarker status, highlighting changes to the treatment recommendations for BRAF V600E mutation-positive disease.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.